Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 8, 2008, Pages 3082-3087

  Canonico, Marianne ^a   Bouaziz, Elodie ^b   Carcaillon, Laure ^a   Verstuyft, Céline ^b,c   Guiochon Mantel, Anne ^a,b   Becquemont, Laurent ^b,c   Scarabin, Pierre Yves ^a  

^a INSERM   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CYTOCHROME P450 1A2; CYTOCHROME P450 3A5; ESTRADIOL; NANDROLONE DERIVATIVE; PREGNANE DERIVATIVE; PROGESTERONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HORMONE METABOLISM; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 49249084660     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0450     Document Type: Article

References (31)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
3. Scarabin PY, Oger E, Plu-Bureau G 2003 Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362:428-432
4. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY 2007 Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115:840-845
5. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand B, et al 1986 Biological effects of estradiol-17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 62:536-541
6. Martucci CP, Fishman J 1993 P450 enzymes of estrogen metabolism. Pharmacol Ther 57:237-257
7. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT 2003 Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144:3382-3398
8. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E 2001 Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
9. Sachse C, Brockmoller J, Bauer S, Roots I 1999 Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449
10. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H 2006 Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 295:1135-1141
11. Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, Tan ZR, Zhou HH 2001 Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 11:429-435
12. Funck-Brentano C, Raphael M, Lafontaine M, Arnould JP, Verstuyft C, Lebot M, Costagliola D, Roussel R 2006 Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. Lung Cancer 54:11-18
13. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY 2005 Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 112:3495-3500
14. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK 2003 Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235
15. Ng FL, Holt DW, MacPhee IA 2007 Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother 8:2045-2058
16. Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE 2005 CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics 15:737-741
17. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Lang F, Eichelbaum M, Strandberg T 2005 CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am J Pharmacogenomics 5:191-195
18. Lieb W, Bolbrinker J, Doring A, Hense HW, Erdmann J, Schunkert H, Kreutz R 2006 No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. Clin Sci (Lond) 111:365-372
19. Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O'Connor DT, Wagner U, Fineberg NS, Weinberger MH 2005 Association between the CYP3A5 genotype and blood pressure. Hypertension 45:294-298
20. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7
21. Slater CC, Hodis HN, Mack WJ, Shoupe D, Paulson RJ, Stanczyk FZ 2001 Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 8:200-203
22. Kuhl H 2005 Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8(Suppl 1):3-63
23. Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV 1997 Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18:207-214
24. Tsuchiya Y, Nakajima M, Yokoi T 2005 Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227:115-124
25. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, Saleh TM 2006 Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 15:551-558
26. Liehr JG 2000 Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21:40-54
27. Swaneck GE, Fishman J 1988 Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 85:7831-7835
28. Huang Z, Guengerich FP, Kaminsky LS 1998 16α-Hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 19:867-872
29. Zhu BT, Conney AH 1998 Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1-27
30. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP 2002 Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22:201-210
31. Simon T, Beau Yon de Jonage-Canonico M, Oger E, Wahl D, Conard J, Meyer G, Emmerich J, Barrellier MT, Guiraud A, Scarabin PY 2006 Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost 4:71-76